Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 2Hodgkin Disease 2Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

romidepsin 12Cyclophosphamide 11Vincristine 9Rituximab 9Etoposide 9Lenalidomide 8Doxorubicin 8Brentuximab Vedotin 8fludarabine 6Prednisone 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Depsipeptides 6fludarabine phosphate 5Mycophenolic Acid 5Lactones 5Gemcitabine 5Cytarabine 5Bendamustine Hydrochloride 5Antilymphocyte Serum 5Whole-Body Irradiation 4Tacrolimus 4Sirolimus 4Methotrexate 4MLN 8237 4Carmustine 4Bortezomib 410-propargyl-10-deazaaminopterin 4thymoglobulin 3duvelisib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell × AFM13 × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Columbia University

Phase 1/2 Completed
18 enrolled 9 charts
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡